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Abstract
Background—We developed an HIV testing dashboard to complement the HIV care continuum 
in selected high-risk populations. Using NHBS data, we examined trends in HIV testing and care 
for men who have sex with men (MSM), persons who inject drugs (PWID) and heterosexuals at 
elevated risk (HET).
Methods—Between 2007–2015, 4,792 participants ≥18 years old completed a behavioral survey 
and were offered HIV testing. For the testing dashboard, proportions ever tested, tested in the past 
year, testing HIV-positive, and newly testing positive were calculated. An abbreviated care 
continuum for self-reported positives (SRP) included ever engagement in care, past year care, and 
current ARV use. The testing dashboard and care continuum were calculated separately for each 
population. Chi-square test for trend was used to assess significant trends over time.
Results—Among MSM, lifetime HIV testing and prevalence significantly increased from 96% to 
98% (p=0.01) and 14% to 20% (p=0.02) over time; prevalence was highest among Black MSM at 
all time points. HIV prevalence among female PWID was significantly higher in 2015 vs. 2009 
(27% and 13%; p<0.01). Among HET from 2010 to 2013, annual testing increased significantly 
(45% to 73%; p<0.001) and the proportion newly diagnosed decreased significantly (p<0.01). SRP 
MSM had high levels of care engagement and ARV use; among SRP PWID and HET, past year 
care engagement and ARV use increased over time.
Conclusions—The HIV testing dashboard can be used to complement the HIV care continuum 
to display improvements and disparities in HIV testing and care over time.
Keywords
HIV testing dashboard; HIV care continuum; National HIV Behavioral Surveillance; Washington; 
D.C
Contact author: Irene Kuo, PhD, MPH, Milken Institute School of Public Health, George Washington University, 950 New Hampshire 
Avenue NW, Suite 500, Washington, DC 20052, Phone: 202-994-0367, Fax: 202-994-0082, ikuo@gwu.edu. 
Conflicts of Interest: The content is solely the responsibility of the authors and does not necessarily represent the official views of the 
NIH.
Findings from this study were presented at the HIV Research for Prevention Conference in Chicago, IL on October 19, 2016.
HHS Public Access
Author manuscript
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 July 01.
Published in final edited form as:
J Acquir Immune Defic Syndr. 2017 July 01; 75(Suppl 3): S397–S407. doi:10.1097/QAI.
0000000000001417.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction
Initiated in 2003, the Center for Disease and Prevention’s (CDC) National HIV Behavioral 
Surveillance (NHBS) system monitors HIV risk behaviors, testing and prevention service 
use among populations most at risk of HIV infection: men who have sex with men (MSM), 
persons who inject drugs (PWID), and heterosexuals at elevated risk (HET).1 Washington, 
DC began contributing data to NHBS in 2006 and has completed three rounds of data 
collection for each population. As the only continuous, routine HIV surveillance system in 
the U.S. that includes HIV negative persons at risk, newly diagnosed HIV-positive, and self-
reported positive (SRP) persons, NHBS provides a unique opportunity to examine patterns 
of HIV testing and HIV care among populations at risk for HIV in Washington, DC over 
time.
HIV testing is the gateway to the HIV prevention continuum including important 
interventions such as pre-exposure prophylaxis (PrEP) and combination prevention.2 It also 
acts as the entry point to linkage to HIV care. Yet due to the nature of HIV core surveillance, 
it is difficult to know who is being tested for HIV, how many people are testing, and how 
frequently they are being tested. Nationally, among populations most at risk for HIV, high 
proportions report having ever been tested for HIV, but significant proportions are still not 
testing annually.3–5 In Washington, DC, a city with high HIV prevalence, the DC 
Department of Health has increased access to HIV testing over the last 10 years, conducting 
163,000 publicly-funded HIV tests in 2014, a 4.3 fold increase since 2006.6–9 NHBS 
assesses lifetime and recent HIV testing in key populations, but these estimates have not 
been comprehensively examined locally to identify gaps in testing coverage and trends in 
testing over time.
In the realm of HIV care, the care continuum displays proportions of HIV-infected persons 
diagnosed, linked to and retained in care, and virally suppressed, and is helpful in 
identifying gaps in care coverage among persons living with HIV.6,10 In 2014, the CDC 
estimated 40% of those diagnosed were engaged in HIV care, 37% were prescribed 
antiretroviral (ARV) treatment and only 30% had achieved viral suppression.11 Since 
persons who are aware of their HIV infection and virally suppressed are less likely to 
transmit HIV, high levels of coverage at each step are integral to HIV prevention and 
reduction of HIV-related morbidity and mortality.12,13
Both HIV testing and care are now seen as necessary components of HIV prevention,2 yet 
few studies have examined these two side by side to present a wider view in a jurisdiction. 
We propose examining HIV testing and HIV prevalence as a testing “dashboard” in order to 
concisely display HIV testing behaviors and HIV prevalence among populations at high-risk 
for HIV over time. Using NHBS data, we aimed to identify trends, gaps, and needs 
regarding both HIV testing and HIV care in community-based populations between 2007 
and 2015 for MSM, PWID and heterosexuals.
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Methods
Sampling and recruitment
NHBS data were used from three data collection cycles each for MSM (MSM cycle 2, or 
MSM2: 2008; MSM3: 2011; MSM4: 2014), PWID (IDU2: 2009; IDU3: 2012; IDU4: 2015), 
and HET (HET1: 2007; HET2: 2010; HET3: 2013). NHBS methods have been described 
elsewhere.1 Briefly, cross-sectional behavioral and HIV testing data are collected in 
repeated, serial cross-sectional, community-based surveys among all three populations. 
Eligibility requirements included being ≥18 years old, a Washington, DC area resident, and 
able to complete the survey in English or Spanish. Conducting interviews in three 
populations also necessitated cycle-specific eligibility criteria. MSM had to be born and 
identify as male and report oral or anal sex with a male partner in the last year. PWID must 
have reported injection drug use in the last year, based on verification of visible injection site 
marks or the ability to describe injection practices. Heterosexuals at elevated risk for HIV in 
HET1 identified as male or female, reported vaginal or anal sex with an opposite sex partner 
in the last year, were 18–50 years old, and lived in high-risk areas, determined based on a 
combination of poverty and AIDS case rates. In the HET2 and HET3 cycles, participants 
must have identified as male or female, had an annual household income below federal 
poverty guidelines or a high school education or less, were 18–60 years old, and reported 
vaginal or anal sex with a person of the opposite-sex in the past year.
NHBS uses two different recruitment methodologies, which have been described previously.
1,14,15
 Venue-based sampling (VBS) is used for the MSM cycle and involves random time–
space sampling.14 Respondent-driven sampling (RDS) is used for the PWID and HET 
cycles. RDS is a chain-referral method which accesses hard to reach populations and 
provides estimates generalizable to the population of networks from which they are drawn.15
Data collection and HIV testing
Eligible and consenting participants completed an interviewer-administered survey and were 
offered a rapid HIV test. HIV testing was voluntary and was not required for study 
participation. All preliminary HIV reactive results and those self-reporting HIV-positive 
status were confirmed via Western Blot, except for the HET1 data collection cycle in which 
the preliminary rapid result was used.16 The NHBS survey assessed demographic 
characteristics, sexual and drug use risk behaviors, HIV testing history, and for SRP 
participants, engagement in care and ARV use. All activities were reviewed and approved by 
the George Washington University and DC Department of Health Institutional Review 
Boards.
Measures—Demographic and behavioral characteristics were assessed for each cycle 
including: age, gender, race, education, income, homelessness in the last year, injection drug 
use ever and in the last year, and non-injection drug use in the last year.
The HIV testing dashboard presents proportions of NHBS participants ever tested for HIV 
(lifetime testing), tested for HIV in the last 12 months, tested HIV-positive, and newly 
positive. Being ever tested for HIV was assessed in the NHBS core questionnaire among all 
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participants. HIV testing in the last year was calculated for those who self-reported HIV-
negative or unknown status and was based on month and year of participant’s last HIV test 
relative to the date of interview. HIV-positive status (i.e., HIV prevalence) was calculated as 
the number of persons with a confirmed NHBS HIV-positive test result (with the exception 
of the HET1 cycle as previously noted—see Magnus et al.)16 divided by the number of 
persons who completed HIV testing for NHBS. Newly-identified HIV-positive status was 
defined as being self-reported HIV-negative or of unknown HIV status in the core 
questionnaire and having a positive NHBS HIV test result.
Persons who self-reported HIV-positive status during the survey were asked questions about 
HIV care engagement. Based on available data, we generated an abbreviated HIV care 
continuum using self-reported data which included the proportion of SRP participants who 
were engaged in care (both ever and in the last 12 months), and who were currently on 
ARVs. Self-reported viral load was not asked until 2015, so viral suppression was excluded 
from this analysis. Engagement in care in the last 12 months was calculated based on the 
self-reported month and year of participant’s last appointment with an HIV provider relative 
to the interview date. Current ARV use was defined as having reported taking ARVs for HIV 
care at the time of interview. Not all SRP persons agreed to HIV testing or were confirmed 
HIV-positive by Western Blot (e.g., indeterminate result), so we assessed differences in the 
HIV continuum for SRP persons with and without serological confirmation. Although the 
number of unconfirmed SRP persons varied by cycle and year, HIV care continuum 
outcomes were not significantly different between those serologically confirmed and 
unconfirmed for all of the populations (data not shown). Therefore, we presented HIV care 
data for all SRP participants. The use of self-reported HIV care outcomes from NHBS is 
consistent with previous national publications.17
Data Analysis—Demographic characteristics were examined for each cycle. Descriptive 
statistics are presented for categorical variables, and medians and interquartile ranges are 
presented for continuous variables. To assess demographic differences across data collection 
years, chi-square tests were conducted for categorical variables and Wilcoxon rank sum tests 
for continuous variables. For RDS cycles, the RDS Analysis Tool (RDSAT) version 8.1 was 
used to create sample weights to adjust for referral patterns, network size and relationship to 
the recruiter in order to obtain population-based estimates which are unbiased to the 
underlying network.18,19 Data for the MSM cycles are unweighted due to lack of data on 
frequency of venue attendance across cycles.20–22 Unweighted analysis of MSM cycle data 
is consistent with previous national and local publications. 23–26
For the HIV testing dashboard, ever tested for HIV and HIV tested in the last 12 months 
were presented as proportions of the total cycle sample, while HIV-positive and newly 
positive are presented as proportions of those who completed NHBS HIV testing. Each 
variable in the abbreviated HIV care continuum for SRP participants was presented as the 
proportion of all SRP participants for that cycle. The HIV testing dashboard and care 
continuum were calculated separately for each population. Trends over time were assessed 
using the chi-square test for trend. To examine differences in HIV testing, data were 
analyzed by race (Black/White/Other) for MSM and gender (male/female) for PWID and 
HET. HIV care continuum data were analyzed by population. We did not assess between-
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population differences in order to focus on trends within each population over time. All 
analyses were completed using SAS version 9.3 (Cary, NC).
Results
Over 10 years, a total of 4,792 eligible participants completed a behavioral survey and were 
offered HIV testing. Table 1 presents demographic characteristics of each cycle completed 
between 2007 and 2015, by cycle and year. Among MSM in Washington, DC, median age 
was significantly higher at 32 years in 2011 compared to 30 in both 2008 and 2014 
(p=0.0097). The proportions of White MSM recruited decreased significantly over time, 
from 48.2% in 2008 to 37.5% in 2014 (p=0.0003). The proportions of MSM reporting at 
least a college degree (56.0% in 2008 vs. 65.6% in 2011 and 64.5% in 2014; p=0.0003) and 
annual income above $50,000 (54.8% in 2008 vs. 60.2% in 2011 and 64.4% in 2014; 
p=0.01) were significantly higher in 2011 and 2014 compared to 2008.
Among PWID between 2009 and 2015, there were several significant differences. Median 
age was higher over time, at 52 years in 2009 to 54 and 55 years in 2012 and 2015, 
respectively (p<0.0001). Across the years, most PWID self-identified as being Black; 
however, the proportion of white PWID sampled increased from 0.7% in 2009 to 5.1% in 
2015 (p<0.0001). The proportion of PWID reporting a high school education or less was 
highest in 2012 (80.9%) compared to 2009 and 2015 (67.3% and 65.6%, respectively, 
p<0.0001). Additionally, in 2009 67.6% of PWID also reported using non-injection drugs in 
the past year, compared to 45.5% in 2012 and 57.2% in 2015 (p<0.0001).
From 2007 to 2013, heterosexuals at elevated risk for HIV were majority female and 
reported income below $20,000 annually. In 2013, the median age was significantly lower 
(35 years old) than in previous cycles (36 and 38.5 years old in 2007 and 2010, respectively, 
p<0.0001). Although most heterosexuals sampled identified as Black, the proportion 
identified as other race was significantly higher in 2010 (8.6%) compared to 4.3% and 7.4% 
in 2007 and 2013, respectively (p=0.002). In 2010, a higher proportion of heterosexuals had 
experienced homelessness in the last year compared to 22.8% and 22.5%, respectively, in 
2007 and 2013 (p<0.0001).
HIV Testing Dashboard
The HIV testing dashboard for MSM (Figure 1) revealed high proportions of lifetime HIV 
testing, with a small but significant increase between 2008 and 2014 (96% to 98%, p=0.01). 
Past year testing also was significantly higher comparing 2008 and 2014 (69% vs. 78%, 
respectively; p=0.003). Among MSM overall, HIV prevalence was highest in 2014 
compared to 2008 and 2011 (20% vs. 14% and 12%, respectively; p=0.02), but the 
proportions of newly HIV-positive MSM over this period were not significantly different 
(6% in 2014 vs. 4% in 2008; p=0.11). Compared to MSM of other races, Black MSM 
reported the largest significant increases, from 2008 to 2014, in lifetime (94% to 99%; 
p=0.001) and past year HIV testing (62% to 77%; p=0.005). Although not statistically 
significant, among Black MSM, HIV prevalence was higher in 2014 compared to 2008 and 
2011 (36% vs. 27% and 24%, respectively; p=0.06) and the proportion newly positive was 
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lower in later years (7% and 7%, 2011 and 2014, respectively) compared to 2008 (12%; 
p=0.12).
Among PWID sampled (Figure 2), being ever tested for HIV did not differ significantly over 
time, while HIV testing in the past year was significantly higher in 2015 compared to 2009 
(78% vs. 66%, respectively p<0.0001). Estimated HIV prevalence was 13% in both 2009 
and 2012, and was significantly different in 2015 at 15% (p<0.0001). Across most time 
points, a higher proportion of male PWID had ever been HIV tested than female PWID. 
Among female PWID, a significantly lower proportion reported ever testing for HIV in 2015 
compared to 2009 and 2012 (85% vs. 91% and 100%, respectively, p=0.045), but past year 
HIV testing was significantly higher in 2015 vs 2009 (81% vs. 60%, respectively, p<0.001). 
Estimated HIV prevalence among female PWID was significantly higher in later years (13% 
in 2009 vs. 17% in 2012 and 27% in 2015; p=0.0005); the HIV prevalence for male PWID 
did not differ over time.
Among sampled heterosexuals at elevated risk for HIV, the proportion who had ever been 
HIV tested remained stable from 2007 to 2013 (Figure 3) (85% to 89%, p=0.12), while past 
year testing rose significantly (45% to 73%, p<0.001). HIV prevalence in HET overall 
ranged from 4% to 8% across years; the proportion newly diagnosed as HIV-positive 
decreased significantly between 2007 and 2013 (2% to 0%, respectively; p=0.003). 
Stratifying by gender, male and female HET participants both reported significant increases 
in past year testing between 2007 and 2013 (male: 40% to 67%, p<0.0001; female: 50% to 
76%, p<0.0001). Estimated prevalence of newly identified HIV infections in both HET 
males and females decreased from 2% in 2007 to 0% in 2013, but this was only statistically 
significant among HET females (p=0.04).
HIV Care Continuum
In Figure 4, among SRP MSM, the proportion who had ever seen an HIV care provider was 
high but did not differ significantly across time (92% to 96%, p=0.36), as was the proportion 
who had seen an HIV care provider in the past 12 months (90% to 92%, p=0.68). Among 
SRP PWID, significantly higher proportions had ever been in care in 2012 and 2015 
compared to 2009 (100% and 97% vs. 69%, respectively, p<0.0001). Additionally, there 
were significant increases from 2009 to 2015 in the proportion who had seen a medical 
provider for HIV care in the past year (65% vs. 89%, p=0.003) and on ARV treatment at the 
time of interview (43% vs. 76%, p=0.0003). Among SRP HET participants, having seen a 
medical provider for HIV care in the past year increased from 51% in 2007 to 86% in 2013 
(p=0.007). While currently being on ARV treatment was higher in 2007 compared to 2013 
(60% vs. 90%, respectively; p=0.045), ARV use in 2010 was particularly low at 28%.
Discussion
We developed an HIV testing dashboard to provide key information on HIV testing coverage 
in high-risk populations to complement the HIV care continuum. The dashboard highlights 
gaps and trends in HIV testing and prevalence in Washington, DC from 2007 to 2015 and 
may also indicate the potential impact of expanded HIV testing programs. HIV testing, both 
lifetime and past year, was highest for all populations in the most recent cycles compared to 
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the first cycle, suggesting important increases in HIV testing coverage over time. This 
reflects national trends, in which MSM reported the highest proportions of past year HIV 
testing and HIV prevalence, compared to PWID and HET.3,4,27 Higher HIV prevalence was 
observed among MSM and PWID in later data collection years, and observed HIV 
prevalence was lower in later years among HET. The abbreviated care continuum showed 
that MSM also had higher levels of engagement in care, both ever and in the past year, and 
ARV use, compared to PWID and heterosexuals.
Among MSM, PWID, and heterosexuals, >80% reported ever testing for HIV, and there 
were significant increases over time in the proportion tested for HIV in the past year. An 
analysis among cities funded through CDC’s Expanded HIV Testing Initiative found a 
similar increase in recent testing between 2008 and 2011 among MSM,28 and Washington, 
DC reports among the highest levels of past year testing in all populations.3,4,27 Over time 
we observed successively higher proportions of engagement in care and ARV use among 
heterosexuals and PWID. This may suggest the increased identification of HIV-positive 
individuals who are linked into care as a result of the expansion of HIV testing and linkage 
services in Washington, DC in the past decade.8,18 In addition, much research and 
programming to increase HIV care engagement has been conducted in Washington, DC, 
which may also have contributed to increased proportions of HIV care engagement observed 
across all populations over time.6,29–35
Despite these promising trends, gaps in annual HIV testing and disparities in HIV 
prevalence persist in each key population, particularly among Black MSM and women. 
While Washington, DC has been successful in increasing HIV testing overall in these 
populations,7 our findings among Black MSM highlight the continued racial disparity in 
HIV prevalence among MSM, seen both nationally and in Washington, DC.9,36 In addition, 
differences in HIV prevalence persisted across time among women compared to men in both 
the HET and PWID cycles in Washington, DC. Participants in the PWID and HET cycles 
predominantly identify as Black, which may partially explain these disparities, as Black 
women continue to be highly affected by HIV.37 Combined, these observed disparities signal 
the need for continued development and implementation of prevention interventions 
focusing on these highly impacted populations.
The National HIV/AIDS Strategy (NHAS) aims to increase retention in care and viral 
suppression among persons living with HIV.38 Our findings suggest that Washington, DC 
has succeeded in increasing engagement in care among HIV-positive MSM, PWID, and 
heterosexuals in the past decade. Specifically, the NHAS aims to increase retention in HIV 
care to 90% for persons living with HIV by 2020. Among MSM surveyed in 2014 for 
NHBS, Washington, DC successfully achieved this goal, and was close to 90% among 
heterosexuals and PWID, based on data from 2013 and 2015, respectively. In the most recent 
data collection cycles, SRP MSM, PWID, and heterosexuals reported higher proportions of 
engagement in care and ARV use compared to national estimates, but it should be noted that 
there are methodological differences between the data used from NHBS and those from the 
National HIV Surveillance System and Medical Monitoring Project.11
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While 10 years of behavioral surveillance data for three high-risk populations provide 
numerous insights into the spectrum of HIV testing and care, these findings should be 
considered in light of their limitations. First, although data for PWID and HET were RDS-
weighted, data from the MSM cycles were unweighted due to lack of information on venue 
attendance; therefore, these data may not be representative of venue-attending MSM or 
MSM who do not attend venues due to the nature of the sampling scheme. While HIV status 
is confirmed by serologic testing, HIV testing and care data are based on self-report, and 
therefore they may be subject to recall and social desirability bias. Although interviewers 
were highly trained and routine data quality checks were conducted, there was the 
possibility of recording errors and intra/inter-interviewer differences in questionnaire 
administration While eligibility and recruitment criteria were consistent across PWID and 
MSM cycles, the eligibility and recruitment criteria differed slightly between HET1 and 
HET2 as noted previously. Lastly, the abbreviated HIV care continuum was based on a small 
sample size and does not include a measure of viral suppression.
Conclusion
The HIV testing dashboard provides a concise view of key HIV testing indicators in high-
risk populations within a jurisdiction that are unique to NHBS data. Together with the 
abbreviated HIV care continuum, the dashboard provides a wider lens through which a more 
complete picture of HIV prevention and treatment activities can be viewed.
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Figure 1. HIV Testing Dashboard for men who have sex with men by NHBS cycle year, 
Washington, DC
*p<0.05, **p<0.01
MSM = men who have sex with men data collection cycle
Other = Asian, American Indian/Alaska Native, Hispanic, Native Hawaiian, Multiracial
Note: HIV test in the last 12 months proportions are of those who self-reported negative/
unknown HIV status (MSM2: n=448; MSM3: n=439; MSM4: n=434).
HIV positive and newly positive proportions are of those who completed NHBS testing
(MSM2: n=484; MSM3: n=490; MSM4: n=455).
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Figure 2. HIV Testing Dashboard for persons who inject drugs (PWID) by NHBS cycle year, 
Washington, DC
*p<0.05, **p<0.01
IDU = injection drug user (or PWID) data collection cycle
Note: HIV test in the last 12 months proportions are of those who self-reported negative/
unknown HIV status
(IDU2: n=504; IDU3: n=484; IDU4: n=476).
HIV positive and newly positive proportions are of those who completed NHBS testing
(IDU2: n=549 ; IDU3: n=508; IDU4: n=513)
All proportions presented are weighted for respondent driven sampling.
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Figure 3. HIV Testing Dashboard for heterosexuals at elevated risk for HIV by NHBS cycle year, 
Washington, DC
*p<0.05, **p<0.01
HET = Heterosexual at elevated risk for HIV data collection cycle
Note: HIV test in the last 12 months proportions are of those who self-reported negative/
unknown HIV status
(HET1: n=735; HET2: n=453; HET3: n=435).
HIV positive and newly positive proportions are of those who completed NHBS testing
(HET1: n=719; HET2: n=480; HET3: n= 456)
All proportions presented are weighted for respondent driven sampling.
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Figure 4. Abbreviated HIV Care Continuum by NHBS data collection cycle and year, 
Washington, DC
*p<0.05, **p<0.01
MSM = men who have sex with men data collection cycle
PWID = people who inject drugs; IDU = injection drug user data collection cycle
HET = heterosexuals at elevated risk for HIV data collection cycle
Note: IDU and HET proportions presented are weighted for respondent driven sampling.
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